Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD Study of ACD856 in Healthy Adults
NCT05077631Phase 1Completed
- Sponsor
- AlzeCure Pharma
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) and cognitive disorder (CD) comparing ACD856 with Placebo (2 arms). Primary endpoints: Frequency of adverse events (AEs) at 8 days, Clinically significant changes in 12-lead ECGs at 8 days and 3 more. Started Feb 2021; status: completed.
02
Drugs
ACD856
03
Conditions
Alzheimer's disease (AD)cognitive disorder (CD)
Beyond the preview
Go deeper on NCT05077631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077631.